Segal Trials is honored to be one of seven sites participating in this exciting Major Depressive Disorder study!
Usona Institute Clinical Trial of Psilocybin for Major Depressive Disorder Launching This Fall September 05, 2019 09:03 AM Eastern Daylight Time MADISON, Wis.–(BUSINESS WIRE)–Usona Institute launches its Phase 2 study of psilocybin for major depressive disorder this fall. The study, PSIL201, will be conducted at seven U.S. sites and will investigate the safety and efficacy of …